Clinical trialNCT07099898RecruitingPhase 3Interventional

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

SponsorGlaxoSmithKlineEnrollment420Neoplasms, Lung

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread. This study specifically aims to evaluate how well Ris-Rez works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether Ris-Rez makes cancers smaller or disappear completely and if it helps participants live longer. The study is also assessing whether Ris-Rez is safe and tolerated well by participants compared to topotecan and provide a better understanding of the main side effects of both drugs. Participants with relapsed SCLC will be randomly divided into two groups: one group receiving Ris-Rez and the other receiving topotecan.

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

144 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Gsk Investigational Site
Mar del Plata, Buenos Aires, Argentina
Ignacio Casarini
Recruiting
Gsk Investigational Site
Buenos Aires, Argentina
Christian Fuentes
Recruiting
Gsk Investigational Site
Ciudad Autonoma de Buenos Aire, Argentina
Pedro Martin Paskevicius
Recruiting
Gsk Investigational Site
Ciudad Autonoma de Buenos Aire, Argentina
Nicolas Minatta
Recruiting
Gsk Investigational Site
Rosario, Argentina
Gabriel Garbaos
Recruiting
Gsk Investigational Site
Vicente López, Argentina
Gustavo Lopez
Recruiting

Australia

Gsk Investigational Site
Blacktown, New South Wales, Australia
Emma Boys
Recruiting
Gsk Investigational Site
St Leonards, New South Wales, Australia
Malinda Itchins
Recruiting
Gsk Investigational Site
Melbourne, Victoria, Australia
Benjamin Solomon
Recruiting
Gsk Investigational Site
Nedlands, Western Australia, Australia
Withdrawn

Brazil

Gsk Investigational Site
Florianópolis, Santa Catarina, Brazil
fabricio grando
Recruiting
Gsk Investigational Site
Barretos, Brazil
Flavio Augusto Ferreira da Silva
Recruiting
Gsk Investigational Site
CuritibaPR, Brazil
Karina Costa Maia Vianna
Recruiting
Gsk Investigational Site
Porto Alegre, Brazil
Katsuki Tiscoski
Recruiting
Gsk Investigational Site
Porto Alegre, Brazil
Ana Gelatti
Recruiting
Gsk Investigational Site
Rio de Janeiro, Brazil
Tatiane Montella
Recruiting
Gsk Investigational Site
São Paulo, Brazil
Gilberto De Castro Junior
Recruiting

Bulgaria

Gsk Investigational Site
Pleven, Bulgaria
Yordan Ignatov
Recruiting
Gsk Investigational Site
Plovdiv, Bulgaria
Vladimir Kanarev
Recruiting
Gsk Investigational Site
Rousse, Bulgaria
Nikolay Nikolaev
Recruiting
Gsk Investigational Site
Sofia, Bulgaria
Withdrawn
Gsk Investigational Site
Sofia, Bulgaria
Krasimir Koynov
Recruiting

Canada

Gsk Investigational Site
Ottawa, Ontario, Canada
Paul Wheatley-Price
Recruiting
Gsk Investigational Site
Toronto, Ontario, Canada
Natasha Leighl
Recruiting
Gsk Investigational Site
Montreal, Quebec, Canada
Jennifer Friedmann
Recruiting
Gsk Investigational Site
Montreal, Quebec, Canada
Kevin Jao
Recruiting

Finland

Gsk Investigational Site
Vaasa, Finland
Ravichandra Ravi
Recruiting

France

Gsk Investigational Site
Boulogne-Billancourt, France
Etienne Giroux Leprieur
Recruiting
Gsk Investigational Site
Grenoble, France
Denis Moro-Sibilot
Recruiting
Gsk Investigational Site
Saint-Herblain, France
Sandrine Hiret
Recruiting
Gsk Investigational Site
Villejuif, France
Pernelle Lavaud
Recruiting

Germany

Gsk Investigational Site
Karlsruhe, Baden-Wurttemberg, Germany
Christian Meyer zum Bueschenfelde
Recruiting
Gsk Investigational Site
Löwenstein, Baden-Wurttemberg, Germany
Jonas Kuon
Recruiting
Gsk Investigational Site
Stuttgart, Baden-Wurttemberg, Germany
Perihan Canoglu
Recruiting
Gsk Investigational Site
Augsburg, Germany
Bjoern Hackanson
Recruiting
Gsk Investigational Site
Chemnitz, Germany
Stefan Hammerschmidt
Recruiting
Gsk Investigational Site
Esslingen am Neckar, Germany
Martin Faehling
Recruiting
Gsk Investigational Site
Heidelberg, Germany
Johannes Schnorbach
Recruiting
Gsk Investigational Site
Immenhausen, Germany
Achim Rittmeyer
Recruiting
Gsk Investigational Site
Lübeck, Germany
Jens Kisro
Recruiting

104 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Risvutatug rezetecanTopotecan →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 11 Aug 2025
Primary completion: 5 Nov 2027
Completion: 28 Sept 2029
Last update posted: 20 Oct 2026
Registered enrollment: 420
Registry id: NCT07099898

Cross-registrations

EU-CTR / CTIS (EudraCT)2025-521627-78-00

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.